ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Graham J. Cooper
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akowuah, E. F.
Right arrow Articles by Newman, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akowuah, E. F.
Right arrow Articles by Newman, C.
Related Collections
Right arrow Molecular biology

Ann Thorac Surg 2003;76:959-966
© 2003 The Society of Thoracic Surgeons

Review

Preventing saphenous vein graft failure: does gene therapy have a role?

Enoch F. Akowuah, MRCSa*, Paul J. Sheridan, MRCPa, Graham J. Cooper, MDb, Christopher Newman, PhDa

a Cardiovascular Research Group, The University of Sheffield, Sheffield, United Kingdom
b Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, United Kingdom

* Address reprint requests to Dr Akowuah, Cardiovascular Research Group, Clinical Sciences North, Northern General Hospital, Herries Rd, Sheffield S5 7AU, UK
e-mail: akowuah{at}yahoo.com

Gene therapy potentially allows local delivery and expression of cytokines, growth factors, and other mediators. In spite of increasing knowledge of the human genome, applications in clinical practice are only just beginning. The main limitations of effective clinical gene therapy are safety and low transfection efficiency. Saphenous vein grafts permit the transfection of the conduit ex vivo. This allows a variety of transfection techniques to be used, enhancing the transfection efficiency while limiting the risk of systemic complications. This review examines the potential mechanisms of gene delivery and genetic targets that may be applied to saphenous vein graft failure.




This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
T. Schachner, C. Steger, S. Heiss, N. Bonaros, W. Sterlacci, G. Laufer, and J. Bonatti
Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins
Eur J Cardiothorac Surg, December 1, 2007; 32(6): 906 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Cardiothorac SurgHome page
T. Schachner, G. Laufer, and J. Bonatti
In vivo (animal) models of vein graft disease
Eur J Cardiothorac Surg, September 1, 2006; 30(3): 451 - 463.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.